RAY DIRKS Research Recommends: Genesis Biopharma (GNBP) March 25, 2011Posted on admin on March 24, 2011 // Leave Your Comment
GENESIS BIOPHARMA, Inc. (GNBP-ob) – $1.10 March 25, 2011
Ray Dirks of RAY DIRKS RESEARCH strongly recommends the common stock of Genesis Biopharma (GNBP), a development stage biotechnology company developing targeted cancer immunotherapies. The company’s platform technologies are being developed initially with a focus on the treatment of colorectal cancer and metastic melanoma. Significant downstream opportunities are available in developing drugs for a number of cancers, other aging related diseases, and infectious disease. The worldwide market for cancer therapies is $60 billion and a key part of big pharma’s revenue growth through acquisition and licensing. Genesis Biopharma is led by an experienced and talented management team with decades of experience leading public biotech companies.
At its current price of $1.10, there is significant capital appreciation potential in the next two to three months. This appreciation will be driven by the U.S. and global investment community becoming aware of the significant and highly favorable developments that Genesis Biopharma is achieving in fighting cancer.
Over the next two to three years, we believe Genesis Biopharma stock will appreciate by twenty to forty times into the $25 to $50 price range as its management rapidly achieves a meaningful number of major milestones in its business model. Genesis Biopharma now has a market capitalization of only $110 million on a fully diluted basis with virtually no debt.
TECHNOLOGY OVERVIEW
Genesis Biopharma has two main immunotherapy technology platforms. These are the anti-CD55+ therapeutic antibody and autologous cell immunotherapy. Immunotherapies help the body’s natural immune system to fight cancer, thus potentially reducing the harmful side effects of drugs currently on the market.
Anti-CD55+ Therapeutic Antibody
The body’s immune system naturally fights many types of cancer through a process called complement-dependent cytotoxicity (CDC). Cancer cells try to defend themselves from the body’s natural CDC defense system by producing CD55, which protects the cancer cells from being destroyed by CDC. Genesis Biopharma’s proprietary anti-CD55+ therapeutic antibody de-activates and neutralizes the CD55 created by cancer cells to protect themselves. Disarming cancer cells of their CD55 allows the body’s immune system to use CDC to kill cancer cells. CD55 is over expressed in more than 80% of solid cancer tumors. Anti-CD55+ has been proven safe in humans. It has been used in imaging technologies to identify tumors in over 300 patients. In these patients, through cancer diagnostic imaging studies, anti-CD55+ identified many tumors, including colorectal, breast, lung, gastric, pancreatic, and osteosarcoma. Anti-CD55+ may be used by itself, or in conjunction with other blockbuster cancer treatments to make those currently available treatments much more effective, up to 280% more effective according to a recent study.
Autologous Cell Immunotherapy
Genesis Biopharma is developing a proprietary technique to supercharge the body’s immune cells to fight cancer. A small amount of immune cells are isolated in the patient and taken out of the body. These immune cells are put in a test tube (in vitro), multiplied, and stimulated to destroy cancer cells. Once super charged, these immune cells are put back into the body. Because they are more sensitized and there are more of them, these cells more effectively to seek out and destroy cancer cells.
Autologous cell immunotherapy is one of the most promising areas in oncology because it uses a patient’s own immune cells to fight their cancer. Genesis Biopharma is currently working to bring together the necessary intellectual property and technology assets, along with the necessary scientific and manufacturing expertise to build out a commercial-scale autologous cell immunotherapy program.
ONCOLOGY MARKET OPPORTUNITY
In a word, the cancer therapy market is ENORMOUS. The worldwide market for cancer therapies is $60 billion and a key part of big pharma’s revenue growth. Oncology (cancer therapy) is the third largest pharmaceutical market in the world with a compound annual growth rate of more than 10% annually.
Big Pharma Looking for New Targeted Therapies
Big pharmaceutical companies are experiencing major competition in the cancer therapy market due to expiration of patents, particularly in the cytotoxic and anti-hormonal markets. As a result, large pharma companies will be actively looking to license and/or acquire new cancer therapy drugs such as those being develop by Genesis Biopharma.
Colorectal Market: Genesis Biopharma’s initial target market
In the colorectal cancer market alone, current therapies have $7 billion in global sales, and the trend is toward targeted therapies in the more than 60% of patients diagnosed with late-stage, aggressive disease.
INTELLECTUAL PROPERTY
Just three months ago, the European Patent Office issued EPO Grant No. 1565494 providing broad coverage on Genesis Biopharma’s anti-CD55+ therapeutic antibody for use as a therapeutic treatment in multiple cancers.
SIGNIFICANT MILESTONES
The Significant Milestones that are likely to be achieved include the following:
1. Discovery and development of additional immunotherapies that enhance natural cancer resistance in a variety of cancers.
2. Discovery and development of drug cocktail assays for therapies that mitigate age-related diseases.
3. Granting of patents for the anti-CD55+ therapeutic antibody in many nations around the world, including the United States.
4. An IND filing (investigational New Drug Application) with the U.S. Food and Drug Administration (FDA) for the company’s drugs.
5. Partnerships with major pharmaceutical and generic biotechnology companies to support clinical development programs.
INVESTMENT HIGHLIGHTS: 5 Reasons to buy the stock
1. The cure to cancer: proprietary, patented immunotherapy for huge cancer market.
The anti-CD55+ monoclonal antibody product candidate enjoys a validated mechanism of action and proven safety. The parent antibody has demonstrated a strong ability to bind specifically to cancerous cells in immunodiagnostic studies, and activities are underway for an IND filing (Investigational New Drug Application) while pursuing partnership interests from major pharmaceutical companies and generic biopharmaceutical companies.
2. Targeting $60 billion market with 10% annual growth rate.
Anti-CD55+ antibody has applicability in a broad range of cancers as a mono-therapy (acting alone, without the use of other cancer drugs) and as a proven synergy with a commercial blockbuster drug. The initial focus is on metastatic colorectal cancer, a $7 billion market and lymphoma.
3. Leading the trend in therapeutics, using the body’s own immune system to beat cancer.
Trends in cancer treatment (oncology) favor targeted therapies. Genesis Biopharma’s therapies boost and work with the body’s natural immune system, thus potentially reducing the side effects of drugs currently on the market.
4. Management team.
Genesis Biopharma’s scientific and business management is incredibly impressive. Managers have decades of public biotech company experience and scientists are experts and leaders in the fields, with dozens of patents to their credit.
5. Undiscovered stock.
Genesis Bipharma recently came public with a $110 million market cap. U.S. and global institutional investors are just now becoming aware of this tremendous opportunity. As more investors get involved in the stock, there is reason to expect higher trading volumes at higher prices.
To view full report: cpreports.com
Disclosure:
The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.
The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
|
